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Objectives: Despite the considerable and growing body of research about the clinical
effectiveness of long-term psychoanalytic treatment, relatively little attention has been
paid to economic evaluations, particularly with reference to the broader range of societal
effects. In this cost-utility study, we examined the incremental cost-effectiveness ratio
(ICER) of psychoanalysis versus psychoanalytic psychotherapy.
Methods: Incremental costs and effects were estimated by means of cross-sectional
measurements in a cohort design (psychoanalysis, n = 78; psychoanalytic
psychotherapy, n = 104). Quality-adjusted life-years (QALYs) were estimated for each
treatment strategy using the SF-6D. Total costs were calculated from a societal
perspective (treatment costs plus other societal costs) and discounted at 4 percent.
Results: Psychoanalysis was more costly than psychoanalytic psychotherapy, but also
more effective from a health-related quality of life perspective. The ICER—that is, the
extra costs to gain one additional QALY by delivering psychoanalysis instead of
psychoanalytic psychotherapy—was estimated at €52,384 per QALY gained.
Conclusions: Our findings show that the cost-utility ratio of psychoanalysis relative to
psychoanalytic psychotherapy is within an acceptable range. More research is needed to
find out whether cost-utility ratios vary with different types of patients. We also encourage
cost-utility analyses comparing psychoanalytic treatment to other forms of (long-term)
treatment.
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Cost-effectiveness
Psychoanalysis is perceived as an expensive ambulatory
treatment for mental illnesses. This high intensity treat-
ment is still covered by national health insurance in Canada,
Australia, and several European countries, including the
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Netherlands. Economic considerations encourage policy
makers and health insurance companies to only fund
evidence-based treatments, which are of minimal burden to
patients and that can be provided in the shortest possible pe-
riod of time. In that light, psychoanalysis is on the brink of
extinction if no evidence can be provided of its effectiveness
in curing particular groups of patients. Perhaps shorter or less
intensive treatments, such as psychoanalytic psychotherapy,
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are more cost-effective compared with psychoanalysis. De-
spite the considerable and growing body of research about
the clinical effectiveness of long-term psychoanalytic treat-
ment (e.g., Leichsenring and Rabung) (15), relatively little
attention has been paid to economic evaluations, particularly
with reference to the broader range of societal effects. Al-
though state-of-the-art cost-effectiveness data are still scarce
for long-term psychotherapy in the Netherlands, the first stud-
ies show promising results (e.g., Bartak et al. and van Asselt
et al.) (3;22). In this light, a study into the cost-effectiveness
of psychoanalysis might be particularly interesting because
this is one of the most expensive ambulatory psychotherapeu-
tic treatments with four to five sessions a week during an aver-
age of 4 to 5 years. Long-term psychoanalytic psychotherapy
has a lower dosage with one to two sessions a week during
an average of 2 to 3 years. A previous study showed that
these two psychoanalytic treatments are commonly assigned
to patients with serious, but roughly comparable, mental
health problems, in particular chronic depression and per-
sonality problems (25). Because of the similarity of the men-
tal health problems at the start of treatment, a comparison
of the cost-effectiveness between the two long-term psycho-
analytic treatments seems reasonable. The general aim of
this study is to investigate how the costs and consequences
of psychoanalysis relate to those of psychoanalytic psycho-
therapy.
Cost-utility analysis is generally recommended as the
preferred economic evaluation method, especially when the
health effects are measured in quality-adjusted life-years
(QALYs; 10). The quality adjustment is based on a set of
weights, called utilities, which reflects the desirability of the
health states. A systematic review on cost-utility analysis
studies of depression treatment showed that psychotherapy
had lower costs per QALY than (primary physician) usual
care (19). In addition, data on cost-effectiveness of psy-
chotherapy for personality disorders suggest that treatment
for patients with a high burden of disease may eventually lead
to cost-savings (3). In cost-utility analyses, health improve-
ment is commonly measured with instruments that describe
and value health-related quality of life over a range of dif-
ferent health states. Such generic instruments can be used
to assess the quality of life within a certain clinical setting
and relate it to reported health states in other settings with-
out having to gather that information in the project itself.
Furthermore, state-of-the-art economic evaluations always
include two different types of costs: (i) direct treatment costs
and (ii) indirect costs associated with healthcare use and lost
productivity related to health problems (21).
The objective of this study was to investigate the es-
timated cost-effectiveness of psychoanalysis delivered by
mental health workers in ambulatory mental health clin-
ics for patients with chronic depression and/or personality
problems in comparison with a lower intensity psychoan-
alytic psychotherapy. Earlier reports have shown that both
forms of psychoanalytic treatment were effective with re-
gard to reducing mental health symptoms and personality
problems (4; Berghout, Zevalkink, & de Jong, unpublished
data, 2009). In this cost-utility study, we examined the incre-
mental cost-effectiveness ratio (ICER) of high-dosage versus
lower-dosage psychoanalytic treatment which estimates the
additional costs that need to be invested to achieve an extra




This multicenter study included 182 subjects from four men-
tal healthcare organizations (Nederlands Psychoanalytisch
Instituut, De Gelderse Roos, Mediant, Parnassia/Psy-Q) who
received either psychoanalysis (PA; n = 78) or psychoana-
lytic psychotherapy (PP; n = 104). In this study, we used a
quasi-experimental, cross-sectional design with three differ-
ent cohorts (20). These cohorts were representative samples
of patients from different phases of treatment. The subjects
followed a naturalistic route through the clinical setting with
treatment assignment performed in teams of experienced
therapists who followed professional guidelines for govern-
ment sponsored long-term ambulatory psychoanalytic treat-
ment. The pretreatment cohort consisted of patients who just
started long-term psychoanalytic treatment (nPA = 25, nPP =
39), the posttreatment cohort consisted of persons who had
just finished long-term psychoanalytic treatment (approxi-
mately 3 months after treatment termination; nPA = 31, nPP =
36), and persons in the follow-up cohort had already finished
their treatment 2 years ago (nPA = 22, nPP = 29). The PA/PP
distribution did not significantly differ between cohorts.
The comparability of the patients in the cohorts was in-
vestigated in two ways. First, we examined pretreatment dif-
ferences between cohorts with regard to sociodemographic
characteristics (gender, age at intake, treatment history, cul-
tural background, educational level, employment status, and
living situation) and psychiatric diagnoses within each treat-
ment group to identify potential confounds (5). For patients
in the PA-group Chi-squared analyses and ANOVA revealed
no significant differences between the three cohorts on pre-
treatment sociodemographic patient characteristics. In the
PP-group, we found cohort differences regarding age at in-
take and living situation: subjects in the posttreatment cohort
were somewhat younger at the start of treatment compared
with subjects in the other two cohorts (F = 3.39; p < .05), and
there were significantly fewer subjects in the posttreatment
cohort who lived with a partner (χ2 = 8.37; p < .05).
Psychiatric diagnoses were assessed following the Di-
agnostic and Statistical Manual of Mental Disorders (DSM-
IV-R) (2) of which three axes are relevant for research: Axis I
(symptoms), Axis II (personality), and Axis IV (general func-
tioning). For DSM-IV-R Axis I, no significant pretreatment
differences between cohorts were found. Most frequently
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diagnosed across all cohorts were mood disorders (44 per-
cent), in particular dysthymic disorder (30 percent) followed
by anxiety disorders (13 percent). The frequencies of Axis II
diagnoses were roughly comparable across the cohorts, how-
ever, in the pretreatment PP-cohort there were significantly
more patients with a diagnosis for a personality disorder
(χ2 = 9.44; p < .01) compared to the other two cohorts.
The majority of the patients (71 percent) was diagnosed
with a personality disorder, in particular personality disor-
der not otherwise specified (29 percent), narcissistic person-
ality disorder (13 percent), dependent personality disorder
(12 percent), and avoidant personality disorder (12 percent).
On Axis V, the average Global Assessment of Functioning
(GAF) score was 64.0 (SD = 7.9). Pretreatment GAF scores
of patients at follow-up were significantly higher compared
with those of patients before and at end of treatment in both
treatment groups (PA: F = 3.77, p < .05; PP: F = 4.38, p <
.05). Maybe it has become customary to estimate the GAF
score lower in light of the threat of budget cuts in recent years
(see also Doidge et al.) (8).
Second, in a random subsample (n = 58), we investi-
gated whether the cohorts had experienced similar processes
with regard to treatment assignment over time and mental
health clinic with the aid of three independent clinicians who
retrospectively assessed the pretreatment GAF and treatment
assignment (PP versus PA) from patient files in which all
information regarding cohort status, mental health organi-
zation, pretreatment psychiatric classification, and treatment
assignment was removed and edited in a similar format. No
significant GAF differences were found. The results showed
that clinical decision making did not change significantly
over time (cohorts) nor differed across the four organizations
(for details, see Berghout et al., unpublished data, 2009). This
supports the hypothesis that a higher GAF in the follow-up
might be a temporally influenced structural adjustment of the
GAF score instead of a selection bias.
Treatments
Both psychoanalytic psychotherapy and psychoanalysis are
open-ended long-term psychotherapeutic treatments, defined
as consisting of at least 25 sessions or lasting at least 1 year.
These psychoanalytic treatments have been described in text-
books (e.g., 10;11;18). In general, psychoanalytic treatments
share some common theoretical assumptions and intend to
influence the working of unconscious processes by either
focusing on conflicts, object relations, the self, and/or in-
teractional processes (11). Psychoanalysis differs from psy-
choanalytic psychotherapy in that patients in psychoanalysis
receive three or more sessions per week lying on the couch,
while patients in psychoanalytic psychotherapy sit face-to-
face and the frequency typically is one or two times a week.
The average length of treatment was 6.46 years for PA (SD =
2.68 yr) and 3.94 years for PP (SD = 2.50 yr). As could be ex-
pected, this difference in treatment duration was significant
(F = 29.0; p < .001). All therapists (n = 87) in the project
were licensed clinicians (psychiatrists/psychotherapists or
psychologists/psychotherapists) and a member of one of the
Netherlands psychoanalytic societies.
Procedure
Inclusion criteria for participation were a minimum age of
18 years, having mastery of the Dutch language, and hav-
ing received or being assigned to long-term psychoanalytic
treatment (>25 sessions, with a minimum frequency of once
a week). Exclusion criteria were the presence of (acute) psy-
chotic symptoms. All participants who met these criteria
were approached by means of mail. When subjects returned
a positive informed consent, they received a package of ques-
tionnaires by regular mail with a stamped return envelope.
Data gathering was done in the period of January 2005 to
June 2007. The set of questionnaires we used in the first
months of the study did not include the SF-36. The num-
ber of patients with missing SF-36 data was highest in the
pretreatment cohort, because we started relatively early with
data collection in this cohort. DSM-IV-R diagnoses were as-
sessed in a consensus meeting of psychiatrists, psychothera-
pists, and test-psychologists at the start of treatment after a
comprehensive personality screening.
Instruments
Health-Related Quality of Life. The Short-Form
Health Survey (SF-36) (24) is a generic self-report mea-
sure of health-related quality of life. The Dutch version of
the SF-36 was used (1), which consists of thirty-six items
and generates scores across eight dimensions of physical and
mental health. In an extensive validation study, the mean
coefficient alpha (internal consistency) of the SF-36 scales
across scales and samples was found to be 0.84 (1). From a
sample of eleven items of the SF-36, Brazier et al. (6) es-
timated a preference-based single index measure, resulting
in the SF-6D index. The SF-6D index can be regarded as
a continuous outcome scored on a 0.29 to 1.00 scale, with
1.00 indicating “full health.” This index introduces prefer-
ence weights into the scoring of descriptive data to generate
health state utility values needed to construct QALYs and
conduct cost-utility analyses (6). Missing values (22 per-
cent) were replaced by using the group mean imputation
method. QALYs were estimated by calculating the average
utility scores (SF-6D index) between the pretreatment and
posttreatment measurements as well as the average scores
between the posttreatment and follow-up measurements and
multiplying it by the time between these measurement points.
We assumed that health status changes between two measure-
ment points were gradual over time so that changes in utility
scores could be approximated by a straight line (9). Sample
sizes were not considered to be too discrepant to consider
alternative statistical methods.
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Direct Treatment Costs. The estimation of direct
treatment costs involves two steps: the measurement of the
quantities of resource use and the assignment of unit costs or
prices (9). Total quantities of resource use could be calculated
for patients who had finished their long-term psychoanalytic
treatment. Three resource units were of importance here: the
pretreatment diagnostic assessment, the number of realized
sessions, and the number of cancelled sessions for which
costs were already made. Data on quantities of resource use
were obtained from administrative records kept by the mental
healthcare organizations. At one of the research sites, there
was no exact session administration before 2001, so for those
patients whose treatments started before 2001, the number
of sessions was calculated assuming an equal distribution
of sessions over time (e.g., 138 sessions in 2001–2003 was
extrapolated to 276 sessions for the period 1999–2003).
For the valuation of resource use, unit costs were based
on data of actual personnel costs of all psychotherapists and
psychiatrists who delivered psychoanalysis or psychoana-
lytic psychotherapy in 2006, including material and overhead
costs. The average session costs were calculated at €115.22,
and the costs associated with the whole pretreatment diagnos-
tic assessment (intake sessions, personality assessment, clin-
ical decision making) were calculated at €3,128. These unit
costs were then multiplied by the quantities of resource use
which resulted in an estimation of the total direct treatment
costs. A discount rate of 4 percent was applied to account for
differential timing of costs (17).
Other Societal Costs. In addition, direct medical
costs and indirect costs were measured with the “Trimbos and
iMTA questionnaire for Costs associated with Psychiatric ill-
ness” (TiC-P) (13). The TiC-P measures costs of relevant uti-
lization of health care other than the psychoanalytic treatment
and indirect costs due to production losses in paid work. We
used the Health and Labor Questionnaire (HLQ) approach
to estimate costs associated with productivity loss at work
(12). With this approach, respondents are asked to estimate
the number of additional hours they should have worked to
compensate for production losses due to illness and reduced
efficiency on working days. For the analysis of long-term ab-
sence from work, we applied the friction-cost method (17).
This limits the indirect costs of productivity losses to the pe-
riod it takes to replace someone who becomes disabled. This
friction period is estimated at 154 days (12). Missing values
(4 percent) were replaced by using the group mean imputa-
tion method. The total societal costs were estimated by cal-
culating the averages between the pretreatment and posttreat-
ment measurements as well as the averages between the post-
treatment and follow-up measurements and multiplying it by
the time between these measurement points. We assumed that
changes in societal costs between two measurement points
were gradual over time. A discount rate of 4 percent was
applied to account for differential timing of costs (17).
Sensitivity Analyses
The usual approach to handling uncertainty in economic eval-
uations is to conduct sensitivity analyses (9). Robustness of
the results was assessed by using three-way sensitivity anal-
yses. We recalculated ICERs by varying discount rates of
treatment costs and other societal costs between 0 percent
and 8 percent, by using the lower confidence limit or the up-
per confidence limit (95 percent confidence interval) of the
incremental effects in QALYs, and by using mean imputation
or no imputation to deal with missing data.
RESULTS
Pretreatment Assessment
For each treatment group, baseline sociodemographic and
diagnostic characteristics of the patients are presented in
Table 1. Chi-squared analyses and ANOVA revealed no
Table 1. Baseline Characteristics of Study Participants in Psychoanalysis (PA) and
Psychoanalytic Psychotherapy (PP)
PA (n = 78) PP (n = 104)
Age, yr: M (SD) 33.2 (7.9) 31.6 (7.9)
Gender
Female 62% 80% ∗∗




Western cultural background 90% 91%
Living with partner 48% 44%
Living with children 22% 18%
Employed 84% 73%
DSM-IV-R diagnoses
Diagnosed with Axis-I disorder 99% 100%
Diagnosed with Axis-II disorder 72% 69%
Global Assessment of Functioning: M (SD) 65.0 (7.3) 63.3 (8.3)
∗∗p < .01.
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Table 2. SF-6D Means and Standard Deviations for a 2 × 3 ANOVA
Phase of treatment
Pretreatment Posttreatment Follow-up
Treatment group M SD M SD M SD
Psychoanalysis (PA) 0.704 (0.05) 0.793 (0.09) 0.757 (0.09)
Psychoanalytic psychotherapy (PP) 0.713 (0.07) 0.767 (0.10) 0.776 (0.09)
Between-subjects effects
df F η2 p
Phase of treatment 2 12.17∗∗∗ 0.12 .000
Treatment group 1 0.00 0.00 .955
Phase of treatment × Treatment group 2 1.20 0.01 .305
Within group error 176 (0.01)
Note. Value enclosed in parentheses represents mean square error. PA: npretreatment = 25, nposttreatment = 31,
nfollow-up = 22; PP: npretreatment = 39, nposttreatment = 36, nfollow-up = 29.∗∗∗p < .001.
ANOVA, analysis of variance.
significant differences between patients in PA and patients
in PP on pretreatment sociodemographic or diagnostic
characteristics, except for the distribution of gender. There
were significantly more women in the PP-group than in the
PA-group (80 percent versus 62 percent; χ2 = 7.38; p < .01).
Before the start of treatment, patients in PA did not dif-
fer significantly from patients in PP with regard to the
SF-6D utility score and direct and indirect healthcare
utilization.
Incremental Cost-Effectiveness Ratio
Table 2 presents the mean SF-6D utility scores for each co-
hort. A 2 (treatment group) × 3 (phase of treatment) inde-
pendent groups analysis of variance was performed to exam-
ine main and interaction effects between treatment groups
and phase of treatment. We found a significant main effect
for phase of treatment, which means that there were signif-
icant differences between the cohorts on the SF-6D index.
These differences were in the expected direction, that is, bet-
ter health status after treatment compared with before treat-
ment. We did not find a main effect for treatment group nor
an interaction effect.
Table 3 presents the average treatment costs and other
societal costs as well as the total costs of PA and PP. The total
treatment costs for PA and PP were calculated by multiplying
the average number of sessions by the basic session cost and
adding the costs associated with the whole pretreatment diag-
nostic assessment (intake sessions, personality assessment,
clinical decision making). The average number of sessions
(including cancelled sessions) in PA was 971, and the average
number of sessions for PP was 180. As expected, psychoanal-
ysis was more expensive than psychoanalytic psychotherapy.
Next, we calculated the number of QALYs achieved. Table 3
shows that more QALYs were achieved after PA as compared
with PP (6.4 versus 4.5, respectively), but that the average
costs per QALY was also higher. The ICER was estimated by
dividing the difference in overall costs by the difference in
QALYs between PA and PP. Table 3 shows that the extra costs
to gain one additional QALY by delivering psychoanalysis
instead of psychoanalytic psychotherapy was €52,384.
Table 3. Total Costs, QALYs, and Average Costs per QALY for Psychoanalysis (PA)
and Psychoanalytic Psychotherapy (PP) and ICER
PA PP Incremental values
Treatment costs (€) 103,507 22,576
Other societal costs (€) 35,593 15,580
Total overall costs (treatment + societal; €) 139,100 38,156 100,944
QALYs 6.384 4.457 1.927
Average costs per QALY (€ /QALY) 21,789 8,561
ICER 52,384
Note. NPA = 78, NPP = 104.
QALYs, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio.
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Table 4. ICER Estimations Based on Three-Way Sensitivity Analyses
Discount rate  QALYs Dealing with missing data ICER estimation
0% Lower confidence limit Mean imputation €61,854/QALY
0% Upper confidence limit Mean imputation €57,518/QALY
0% Lower confidence limit No imputation €64,098/QALY
0% Upper confidence limit No imputation €55,678/QALY
8% Lower confidence limit Mean imputation €48,217/QALY
8% Upper confidence limit Mean imputation €44,837/QALY
8% Lower confidence limit No imputation €49,967/QALY
8% Upper confidence limit No imputation €43,403/QALY
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years.
Sensitivity Analyses
The lower bound estimation of incremental QALYs was es-
timated at 1.857, and the upper bound estimation of incre-
mental QALYs was estimated at 1.997. Incremental costs at a
discount rate of 0 percent were estimated at€114,864, and in-
cremental costs at a discount rate of 8 percent were estimated
at €89,540. Table 4 shows the recalculated ICERs across
varying discount rates and varying estimations of QALY
differences. We found a small to moderate degree of vari-
ation in ICER estimations, supporting the robustness of the
results.
DISCUSSION
In this study, we presented a cost-utility analysis to address
the relative effectiveness and costs of two forms of long-term
ambulatory psychoanalytic treatment using a cross-sectional
cohort design. We combined pretreatment, posttreatment,
and follow-up estimates of health-related quality of life and
costs to provide incremental cost-effectiveness ratios and the
average cost per QALY. The results showed that psychoanal-
ysis was more expensive than psychoanalytic psychother-
apy, but also more effective in terms of QALYs gained. The
ICER of psychoanalysis compared with psychoanalytic psy-
chotherapy showed that the cost of one QALY gained was just
over €52,000. Whether or not psychoanalysis provides good
value for money compared with psychoanalytic psychother-
apy depends on the threshold of the ICER as is acceptable in
the society at hand. From the literature, it becomes clear that
estimates of this threshold vary from €12,000 to €73,000
per extra QALY in the Netherlands (7). The literature also
reveals that estimates of acceptable threshold values tend
to increase in patient populations with life-threatening dis-
eases and higher burden of disease. Our results suggest that
the cost-utility ratio of psychoanalysis relative to psycho-
analytic psychotherapy appears to be within the acceptable
range when lenient threshold values are applied, but it be-
comes less cost-effective when stricter threshold values are
used. The results should be interpreted with caution due to the
design, which brings biases from both sampling and timing
differences.
We used state-of-the-art instruments to assess health-
related quality of life and direct and indirect societal costs.
With the SF-6D, it is possible to examine whether a treatment
has a clinically relevant effect on health-related quality of
life, as the minimally important difference (MID) for the SF-
6D utility scores has been estimated to be 0.033 points (23).
Utility scores for patients receiving psychoanalysis increased
with 0.089 from pretreatment to posttreatment. For patients in
psychoanalytic psychotherapy, the increase in utility scores
from pretreatment to posttreatment was 0.054. From this, we
can conclude that both treatments had a clinically relevant
effect on health-related quality of life as it exceeds 0.033.
The SF-36 is a generic measure and not so much targets the
specific areas in which our patients experience problems. In
this way, it is possible to compare patient populations. Al-
though not relevant for cost-utility analysis, we tentatively
examined the SF-36 subscales. It appeared that our patient
population showed significantly worse health-related qual-
ity of life scores in several areas (mainly mental problems)
before treatment as compared to the age- and sex-adjusted
reference scores from the Dutch general population (1). How-
ever, our patients did not report many physical problems and
were actually functioning quite well in these areas at the start
of treatment. With the TiC-P, we generated data on direct
medical costs following a standard procedure. It included
costs associated with productivity loss at work, which was
particularly relevant to our study population. As advised by
the developers of the instrument, we decided not to consider
costs of medication use, because of the immense diversity in
medications used and relatively low costs associated with it.
By including the TiC-P, we tried to adopt a broad societal
perspective. Nonetheless, we are aware that we are still deal-
ing with imperfect estimates of true overall costs for society.
As Lazar et al. (14) pointed out, remote savings such as re-
duced healthcare consumption and increased productivity of
the patient’s family members, should ideally be included, but
are obviously difficult to measure.
Even in the most carefully designed study, data for all
patients are unlikely to be complete. Group mean imputa-
tion generates ‘replacement’ values for missing data that
will permit complete case analysis using the whole data set.
While mean imputation is one of the most commonly used
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methods to deal with missing data in economic evaluations,
Oostenbrink and Al (16) state that one should be cautious
to apply relatively simple methods such as mean imputation
to deal with missing data, because it can often lead to bi-
ased estimates. We had to deal with a fairly large amount
of missing SF-6D data, so these estimations were associated
with the most uncertainty. The sensitivity analyses revealed,
however, that this uncertainty impacted the estimations of the
cost-effectiveness ratios only to a moderate extent.
In cross-sectional cohort designs, a potential form of
confounding involves differences in background characteris-
tics and level of pretreatment psychopathology between the
cohorts. One cannot be sure that the patients enrolled in the
various cohorts were entirely equivalent in terms of baseline
psychopathology and background characteristics. Pretreat-
ment differences could potentially influence the results of
our cohort comparisons. To investigate bias, we compared
the three cohorts on pretreatment DSM-IV-R diagnoses, so-
ciodemographic characteristics and clinical decision making
and found very few significant differences. Although we re-
alize that there might be other variables—which we did not
measure—that could have relevance to potential confounds,
we have checked the comparability of the cohorts on sev-
eral variables and found no significant sampling bias. The
present cross-sectional cohort design was set up to gather
data about costs and effects of long-term treatments within
a relatively short period of time. We encourage future stud-
ies on the cost-utility of long-term psychoanalytic treatment
to also include true longitudinal research designs. In addi-
tion, we encourage cost-utility analyses of psychoanalytic
treatment compared with other forms of (long-term) treat-
ment. Our study has shown that psychoanalysis is indeed
more costly compared with psychoanalytic psychotherapy,
but also more effective from a health-related quality of life
perspective. The cost-utility ratio of psychoanalysis relative
to psychoanalytic psychotherapy appeared to be within the
acceptable range, however, when one uses stricter thresholds
psychoanalysis becomes less cost-effective than psychoan-
alytic psychotherapy. More research is needed to find out
which types of patients have benefited more from psycho-
analysis as compared to psychoanalytic psychotherapy.
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